CAR-T Meeting 2025 | Effective strategies in anti-GBM CAR-T cells
Denis Migliorini, MD, University of Geneva, Geneva, Switzerland, discusses the growing number of approaches to CAR T-cell therapy, including bispecific approaches tackling tumor antigen specificity, synodical constructs recognizing tumor-specific peptides, and vectorology using RNA to modify T-cells and electroporate multiple CARs. Dr Migliorini highlights the field’s rapid growth and potential for breakthroughs in the next few years, with various approaches combining with innate immune system activation. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
